Search hospitals > Michigan > Farmington
Weisberg Cancer Treatment Center
Claim this profileFarmington, Michigan 48334
Global Leader in Cancer
Global Leader in Adenocarcinoma
Conducts research for Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
185 reported clinical trials
27 medical researchers
Summary
Weisberg Cancer Treatment Center is a medical facility located in Farmington, Michigan. This center is recognized for care of Cancer, Adenocarcinoma, Breast Cancer, Lung Cancer, Recurrence and other specialties. Weisberg Cancer Treatment Center is involved with conducting 185 clinical trials across 261 conditions. There are 27 research doctors associated with this hospital, such as Ammar Sukari, Hirva Mamdani, MD, Anteneh A. Tesfaye, and Anthony F. Shields.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Adenocarcinoma
Global LeaderStage IV
Stage III
Stage II
Top PIs
Ammar SukariWayne State University/Karmanos Cancer Institute1 year of reported clinical research
Expert in Squamous Cell Carcinoma
Expert in Cancer
27 reported clinical trials
44 drugs studied
Hirva Mamdani, MDKarmanos Cancer Institute4 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Studies Lung Cancer
20 reported clinical trials
29 drugs studied
Anteneh A. TesfayeWayne State University/Karmanos Cancer Institute4 years of reported clinical research
Studies Colorectal Cancer
Studies Tumors
18 reported clinical trials
37 drugs studied
Anthony F. ShieldsBarbara Ann Karmanos Cancer Institute4 years of reported clinical research
Studies Solid Tumors
Studies Tumors
20 reported clinical trials
62 drugs studied
Clinical Trials running at Weisberg Cancer Treatment Center
Breast Cancer
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Carcinoma
Squamous Cell Carcinoma
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Gastric Cancer
Pancreatic Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Weisberg Cancer Treatment Center?
Weisberg Cancer Treatment Center is a medical facility located in Farmington, Michigan. This center is recognized for care of Cancer, Adenocarcinoma, Breast Cancer, Lung Cancer, Recurrence and other specialties. Weisberg Cancer Treatment Center is involved with conducting 185 clinical trials across 261 conditions. There are 27 research doctors associated with this hospital, such as Ammar Sukari, Hirva Mamdani, MD, Anteneh A. Tesfaye, and Anthony F. Shields.